Open AccessExploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives
Author(s) -
William P. Katt,
Cody Aplin,
Richard A. Cerione
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s329262
Subject(s) - tissue transglutaminase , context (archaeology) , glioblastoma , medicine , neuroscience , disease , cancer , bioinformatics , cancer research , enzyme , pathology , biology , biochemistry , paleontology
Tissue transglutaminase (tTG) is a rather unique GTP-binding/protein crosslinking enzyme that has been shown to play important roles in a number of cellular processes that impact both normal physiology and disease states. This is especially the case in the context of aggressive brain tumors, such as glioblastoma. The diverse roles played by tTG in cancer survival and progression have led to significant interest in recent years in using tTG as a therapeutic target. In this review, we provide a brief overview of the transglutaminase family, and then discuss the primary biochemical activities exhibited by tTG with an emphasis on the role it plays in glioblastoma progression. Finally, we consider current approaches to target tTG which might eventually have clinical impact.